Lilly battles five-year flu: Analysts: Drugmaker primed for rebound from Prozac defeat
It’s been a challenging five years for Eli Lilly and Co., which has launched nine new drugs yet seen the price of its stock fall by half, wiping out more than $60 billion in market value. However, company officials say the drugmaker has rallied from the jarring setback it received Aug. 9, 2000-when a federal appeals court invalidated Prozac’s patent protection-and are optimistic better times lie ahead. They say the company is positioned to increase profit and revenue, thanks to…